Greg Ball

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/299865/publications.pdf

Version: 2024-02-01

		1683354	1473754	
13	93	5	9	
papers	citations	h-index	g-index	
13	13	13	28	
all docs	docs citations	times ranked	citing authors	

#	Article	lF	CITATIONS
1	Aggregate Safety Assessment Planning for the Drug Development Life-Cycle. Therapeutic Innovation and Regulatory Science, 2021, 55, 717-732.	0.8	8
2	Interdisciplinary Safety Evaluation for Learning and Decision-Making. Therapeutic Innovation and Regulatory Science, 2021, 55, 705-716.	0.8	3
3	Meta-analysis of blinded and unblinded studies for ongoing aggregate safety monitoring and evaluation. Contemporary Clinical Trials, 2020, 95, 106068.	0.8	3
4	Bayesian Meta-analysis of Safety Outcomes Using Blinded Clinical Trial Data. Therapeutic Innovation and Regulatory Science, 2020, 54, 1557-1565.	0.8	4
5	A Framework for Safety Evaluation Throughout the Product Development Life-Cycle. Therapeutic Innovation and Regulatory Science, 2020, 54, 821-830.	0.8	7
6	Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions. Therapeutic Innovation and Regulatory Science, 2020, 54, 447-461.	0.8	6
7	Bridging blinded and unblinded analysis for ongoing safety monitoring and evaluation. Contemporary Clinical Trials, 2019, 83, 81-87.	0.8	5
8	The importance of crossâ€disciplinary scientific engagement in the development of quantitative procedures for aggregate safety assessments. Pharmaceutical Statistics, 2019, 18, 510-512.	0.7	3
9	Blinded Safety Signal Monitoring for the FDA IND Reporting Final Rule. ICSA Book Series in Statistics, 2016, , 201-211.	0.0	7
10	A Bayesian Exposure-Time Method for Clinical Trial Safety Monitoring With Blinded Data. Therapeutic Innovation and Regulatory Science, 2016, 50, 833-838.	0.8	18
11	Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Contemporary Clinical Trials, 2011, 32, S11-S17.	0.8	12
12	Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Contemporary Clinical Trials, 2011, 32, S2-S4.	0.8	17
13	Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions. Therapeutic Innovation and Regulatory Science, 0, , 216847901984131.	0.8	0